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were then incubated in Apoptosis/Necro-
sis Detection Kit buffer containing 1% v/
v 7-AAD and Annexin V-Cy3 (Enzo
LifeSciences, Farmingdale, NY), and sub-
jected to flow cytometry.
Treatment with LsV or recLiD1
caused HFF-1 cell death after 48 hours,
primarily due to apoptosis, which was
not inhibited by Ki16425 (Figure 2a).
The lack of inhibition was expected, as
treatment with LPA did not cause cell
death. Control LPC did not injure cells
either (data not shown). As LPA can
act as a cell survival or apoptotic
factor, dependent upon the cell type
(Ye et al., 2002), we performed the
same procedures using human
umbilical vein endothelial cells, which
yielded similar results (Figure 2b).
Thus, we did not find that LPA parti-
cipates in apoptosis induced by LsV or
recLiD1 in fibroblast and endothelial
cells in vitro. These cells are known
sites of Loxosceles venom interaction.
Our results support the idea that PLD
initiates the effects of Loxosceles venom
through stimulation of acute inflamma-
tory responses.
In conclusion, LPA receptors are in-
volved in the release of proinflammatory
cytokines/chemokines provoked by LsV
and recLiD1. The present work contri-
butes to the open discussion regarding
the participation of LPA in the patho-
physiology of cutaneous loxoscelism
and paves the way for investigation of
new therapeutic strategies.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by CNPq, CAPES, and
FAPEMIG. We thank IEF/MG for the permission for
spider collection. This study was developed in Belo
Horizonte, Minas Gerais, Brazil.
Carolina C.R. Horta1,
Ba´rbara B.R. Oliveira-Mendes1,
Anderson O. do Carmo1,
Fla´via F. Siqueira1, Tatiana M. Barroca1,
Samyra M. dos Santos Nassif Lacerda2,
Paulo H. de Almeida Campos Jr2,
Luiz R. de Franc¸a2, Rodrigo L. Ferreira3
and Evanguedes Kalapothakis1
1Departamento de Biologia Geral, Instituto de
Cieˆncias Biolo´gicas, Universidade Federal de
Minas Gerais, Belo Horizonte, Brazil;
2Departamento de Morfologia, Instituto de
Cieˆncias Biolo´gicas, Universidade Federal de
Minas Gerais, Belo Horizonte, Brazil and
3Setor de Zoologia, Departamento de Biologia,
Universidade Federal de Lavras, Lavras, Brazil
E-mail: ekalapo@icb.ufmg.br
REFERENCES
Barbaro KC, Knysak I, Martins R et al. (2005) Enzy-
matic characterization, antigenic cross-reactivity
and neutralization of dermonecrotic activity of
five Loxosceles spider venoms of medical impor-
tance in the Americas. Toxicon 45:489–99
Barbaro KC, Lira MS, Arau´jo CA et al. (2010)
Inflammatory mediators generated at the site
of inoculation of Loxosceles gaucho spider
venom. Toxicon 56:972–9
Chaim OM, da Silveira RB, Trevisan-Silva D et al.
(2011) Phospholipase-D activity and inflam-
matory response induced by brown spider
dermonecrotic toxin: endothelial cell mem-
brane phospholipids as targets for toxicity.
Biochim Biophys Acta 1811:84–96
Chatzaki M, Horta CC, Almeida MO et al. (2012)
Cutaneous loxoscelism caused by Loxosceles
similis venom and neutralization capacity of
its specific antivenom. Toxicon 60:21–30
Dragulev B, Bao Y, Ramos-Cerrillo B et al. (2007)
Upregulation of IL-6, IL-8, CXCL1, and CXCL2
dominates gene expression in human fibroblast
cells exposed to Loxosceles reclusa sphingo-
myelinase D: insights into spider venom der-
monecrosis. J Invest Dermatol 127:1264–6
Fang X, Yu S, Bast RC et al. (2004) Mechanisms for
lysophosphatidic acid-induced cytokine pro-
duction in ovarian cancer cells. J Biol Chem
279:9653–61
Felicori L, Araujo SC, de Avila RA et al. (2006) Func-
tional characterization and epitope analysis of a
recombinant dermonecrotic protein from Loxo-
sceles intermedia spider. Toxicon 48:509–19
Kalapothakis E, Araujo SC, de Castro CS et al.
(2002) Molecular cloning, expression and
immunological properties of LiD1, a protein
from the dermonecrotic family of Loxosceles
intermedia spider venom. Toxicon 40:1691–9
Kalapothakis E, Chatzaki M, Gonc¸alves-Dornelas
H et al. (2007) The Loxtox protein family in
Loxosceles intermedia (Mello-Leita˜o) venom.
Toxicon 50:938–46
Lee S, Lynch KR (2005) Brown recluse spider
(Loxosceles reclusa) venom phospholipase D
(PLD) generates lysophosphatidic acid (LPA).
Biochem J 391:317–23
Silvestre FG, de Castro CS, de Moura JF et al.
(2005) Characterization of the venom from
the Brazilian Brown Spider Loxosceles similis
Moenkhaus, 1898 (Araneae, Sicariidae). Tox-
icon 46:927–36
Van Meeteren LA, Frederiks F, Giepmans BN et al.
(2004) Spider and bacterial sphingomyeli-
nases D target cellular lysophosphatidic acid
receptors by hydrolyzing lysophosphatidyl-
choline. J Biol Chem 279:10833–6
Van Meeteren LA, Stortelers C, Moolenaar WH
(2007) Upregulation of cytokine expression in
fibroblasts exposed to Loxosceles sphingo-
myelinase D: what is the trigger? J Invest
Dermatol 127:1266–7
Ye X, Ishii I, Kingsbury MA et al. (2002) Lysopho-
sphatidic acid as a novel cell survival/apoptotic
factor. Biochim Biophys Acta 1585:108–13
Zhang Q, Peyruchaud O, French KJ et al. (1999)
Sphingosine 1-phosphate stimulates fibronec-
tin matrix assembly through a Rho-dependent
signal pathway. Blood 93:2984–90
Mutations in ERBB4 May Have a Minor Role in Melanoma
Pathogenesis
Journal of Investigative Dermatology (2013) 133, 1685–1687; doi:10.1038/jid.2013.27; published online 21 February 2013
TO THE EDITOR
In the recent past, an increasing amount
of evidence has indicated that several
alterations to the complex molecular
machinery that provides checks and
balances in normal melanocytes may
be involved in the pathogenesis of mela-
noma (Palmieri et al., 2009; Tsao et al.,
2012). The different molecular pathways
associated with melanomagenesis seem
to correspond to specific subsets of
melanoma patients, with distinguished
biological and clinical behavior of the
disease. In the era, just begun, of
innovative targeted therapies for the
treatment of melanoma (Ascierto et al.,
2012; Flaherty et al., 2012), identi-
fication of such different subsets of
melanoma patients is becoming
mandatory.Accepted article preview online 22 January 2013
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In an attempt to isolate and character-
ize molecular targets for new thera-
peutic opportunities, great efforts have
been focused on mutational analyses
of protein tyrosin kinases, molecules
acting as signal transduction effectors
(Easty et al., 2011). Among others,
the members of the epidermal growth
factor family of transmembrane
receptors (ERBB family) seem to have
an important role as regulators of several
signaling pathways; some of these
family members (ERBB1/EGFR and
ERBB2/HER2) have been shown to
be pathogenetically implicated in a
large fraction of human cancers
(Rudloff and Samuels, 2010). In 2009,
the ERBB4 gene, an additional member
of the ERBB family, was found to
be somatically mutated in 19% of 79
patients with cutaneous melanoma; a
vast majority of mutations were located
in gene segments corresponding to
the functional domains of the ERBB4
protein, inducing its oncogenic activa-
tion (Prickett et al., 2009).
Such findings seemed to reveal a new
therapeutic target in melanoma patients
(Settleman, 2009). In this regard, small-
molecule tyrosine kinase inhibitors have
been demonstrated to promote cancer-
growth arrest by interacting with the
ERBB4 receptor (Carrasco-Garcı´a et al.,
2011), and the presence of a mutated
ERBB4 protein seems to increase the
cell sensitivity to such inhibitors
(Dutton-Regester et al., 2012). As the
original report (Prickett et al., 2009),
next-generation sequencing studies
show much lower incidence of ERBB4
mutations (Dutton-Regester et al.,
2012; Hodis et al., 2012; Krauthammer
et al., 2012). As one possible cause
of discrepancy could be the source
of melanoma, we here further address
this issue by sequencing the ERBB4 gene
in melanoma cell lines and tissues.
A panel of 109 different types of
melanoma samples was screened for
ERBB4 mutations: melanoma cell lines
(n¼ 33), primary melanomas (n¼22),
and paired metastases (removed syn-
chronously or asynchronously with pri-
mary tumors) from the same patients
(n¼ 28) and distinct primary melanomas
from different patients (n¼26).
Genomic DNA was isolated from paraf-
fin-embedded tumor tissues or mela-
noma cell lines, using standard
methods. Products obtained by PCR
assays and corresponding to the full
coding sequences and splice junctions
of the ERBB4 gene were directly
sequenced using an automated fluores-
cence-cycle sequencer, as previously
described (Casula et al., 2009).
Overall, five ERBB4 mutations were
found in 7 (21%) out of 33 melanoma
cell lines; conversely, a mutated ERBB4
gene was detected in primary and
metastatic melanomas from one single
patient (1/48 (2.1%) primary
melanomas; 1/28 (3.6%) melanoma
metastases) (Table 1). Three ERBB4 var-
iants (E452K, E872K, and R1174Q) have
been described as activating mutations
by Prickett et al. (2009), whereas the
remaining three variants with unknown
significance on function (L369I, G918E,
and G1217E) have not been reported
previously in databases or in the
literature. No differences with respect
to the ERBB4 protein levels were
detected by western blot analysis in
Table 1. Samples positive for ERBB4 mutations
A
ERBB4
BRAF NRAS
Cell line Tissue origin Exon Mutation mutation mutation
A, melanoma cell lines originating from primary (n¼ 8) and metastatic (n¼25) melanoma tissues
LB-24-Mel Skin metastasis 9 L369I None None
Mel-74 Lymph node metastasis 9 L369I V600E None
LCP-Mel Primary tumor 21 E872K V600R None
GL-Mel Lymph node metastasis 21 E872K None None
LCM-Mel Lymph node metastasis 21 E872K V600R None
SN-Mel Skin metastasis 23 G918E V600E None
28 G1217E
SBCL2 Primary tumor 28 R1174Q None Q61K
B
ERBB4
BRAF NRAS
Tissue sample Exon Mutation mutation mutation
B, in vivo melanoma tissues
Primarya 12 E452K V600E None
Metastatica 12 E452K V600E None
aFrom the same patient.
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ERBB4 mutant or wild-type melanoma
cell lines (data not shown).
Although the rate of ERBB4 mutations
in our subset of cultured melanomas was
consistent with the one reported in mela-
noma tissues by Prickett et al. (2009)
(21% vs. 19%, respectively), E452K
was instead the only mutation in the
ERBB4 gene observed in 2 (2.6%) out of
76 in vivo melanomas from our series.
Interestingly, the ERBB4-E452K variant
has been previously classified as a hot-
spot mutation, occurring in a represen-
tative proportion of melanomas (Dutton-
Regester et al., 2012).
The very low mutation frequency
observed in tumor tissues from the pre-
sent study seems to replicate the findings
reported by Dutton-Regester et al.
(2012), supporting their conclusions that
ERBB4 mutations may be rare or case-
specific in patients with cutaneous
melanoma. As a confirmation of this,
the ERBB4 gene was found not signifi-
cantly mutated in a recent sequencing-
based screening of the exomes of 147
melanomas (Krauthammer et al., 2012).
Conversely, ERBB4 mutations might be
somehow selected during the acquisition
of a more malignant phenotype and a
higher tendency to proliferate, similar
to that occurring during the in vitro
stabilization of melanoma cells.
In this regard, a vast majority
(5/7; 71%) of tumor cell lines with
ERBB4 mutations from our series also
contained NRAS (n¼ 1) or BRAF (n¼4)
mutations; moreover, the two mela-
noma tissues with a mutated ERBB4
gene also carried a BRAF mutation
(Table 1). These latter observations
may suggest that: (a) there is no appar-
ent enrichment of ERBB4 mutations
in BRAF/NRAS mutant melanoma
cells, and, thus, mutations in this
gene may coexist with those in NRAS
or BRAF (a similar scenario has
been described for PTEN losses or
PIK3CA mutations in melanoma and
colorectal cancer carrying mutations in
RAS or BRAF (Pharoah, 2009; Palomba
et al., 2012)); and (b) the ERBB4
mutations may act as ‘‘passenger’’
instead of ‘‘driver’’ genetic alterations
in melanoma pathogenesis (one
could speculate that such gene variants
may be associated with a deregulated
proliferation status—which is mainly
driven by constitutive activation of
the NRAS-/BRAF-depending pathways,
particularly prevalent among the
cultured melanoma cells). Although in
a limited subset of melanomas, the
coexistence of ERBB4 and BRAF
mutations could provide an additional
tool for developing combination strate-
gies for targeted therapies (BRAF and/or
MEK inhibitors, which are currently
investigated in patients with BRAF or
NRAS mutations (Flaherty et al., 2012),
could be associated with inhibitors of
the ERBB family kinases, such as
lapatinib (Prickett et al.,2009; Dutton-
Regester et al., 2012)).
Large-scale exome analyses (Hodis
et al., 2012; Krauthammer et al.,
2012), as well as ongoing whole-
genome sequencing approaches, in
melanoma patients would hopefully
clarify both the spectrum and impact
of the different somatic mutations
underlying melanomagenesis or the
molecular classification of the disease
for therapeutic or prognostic purposes.
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